AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 21209231
Drug: Sitagliptin 200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sitagliptin 200 mg/day (2 × 100 mg tablets)
Trial: 19216606
Drug: Chlorhexidine solution
RxNorm normalized name: CHLORHEXIDINE GLUCONATE 99.0 g in 1 L TOPICAL SOLUTION [CHLORHEXIDINE Solution]
DrugBank: Chlorhexidine (DB00878)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Chlorhexidine solution (2%)
Trial: 19216606
Drug: Chlorhexidine gel
RxNorm normalized name: chlorhexidine Oral Gel
DrugBank: Chlorhexidine (DB00878)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Chlorhexidine gel (1%)
Trial: 19216606
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no chlorhexidine treatment)
Trial: 17944273
Drug: Inhaled ribavirin
RxNorm normalized name: ribavirin Inhalation Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled ribavirin
Trial: 17944273
Drug: Promising new
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Promising new agents
Trial: 11574372
Drug: Levobupivacaine 0.125%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levobupivacaine 0.125% with sufentanil 0.75 microg/mL and epinephrine 1.25 microg/mL
Trial: 11574372
Drug: Racemic bupivacaine
RxNorm normalized name: Racemic bupivacaine
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Racemic bupivacaine 0.125% with sufentanil 0.75 microg/mL and epinephrine 1.25 microg/mL
Trial: 9634262
Drug: Steam-distilled garlic
RxNorm normalized name: petroleum distillate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Steam-distilled garlic oil preparation (5 mg twice a day)
Trial: 7945742
Drug: Antidepressant medications
RxNorm normalized name: ANTIDEPRESSANTS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antidepressant medications with a placebo run-in period
Trial: 7945742
Drug: Antidepressant medications
RxNorm normalized name: ANTIDEPRESSANTS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antidepressant medications with a post-randomization placebo treatment cell
Trial: 1968233
Drug: Idazoxan (alpha‐2‐adrenoceptor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Idazoxan (alpha‐2‐adrenoceptor antagonist)
Trial: 1968233
Drug: Idazoxan and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Idazoxan and naloxone combination
Trial: 30811963
Drug: Lorcaserin (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lorcaserin (10 mg)
Trial: 28011247
Drug: Nebulized arformoterol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nebulized arformoterol 15 µg BID
Trial: 23382470
Drug: Corticorelin acetate
RxNorm normalized name: Corticorelin acetate
DrugBank: Corticorelin acetate (DB12915)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Corticorelin acetate (CrA) 1 mg twice per day
Trial: 21269553
Drug: Epley's manoeuvre
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epley's manoeuvre plus labyrinthine sedative
Trial: 19167712
Drug: Atorvastatin 80mg/d
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atorvastatin 80mg/d
Trial: 19167712
Drug: Atorvastatin 10mg/d
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atorvastatin 10mg/d
Trial: 15502038
Drug: 0.25 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.25 mg/kg mivacurium (MV group, n = 10)
Trial: 15502038
Drug: 0.1 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.1 mg/kg pancuronium (PC group, n = 10)
Trial: 10661294
Drug: Nutritional support
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nutritional support with enriched food supplements
Trial: 29813097
Drug: B‐vitamins alone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: B‐vitamins alone (560 μg of 5‐methyl‐THF, 3 mg of vitamin B6 and 20 μg of vitamin B12)
Trial: 29813097
Drug: n‐3 fatty
FDA approved: no
EMA approved: no
PMDA approved: no
Description: n‐3 fatty acids alone (600 mg of EPA and DHA in a 2:1 ratio)
Trial: 27578110
Drug: DHA-enriched fish
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DHA-enriched fish oil (2.4 g per day for 8 weeks)
Trial: 8792890
Drug: Lidocaine aerosol
RxNorm normalized name: Lidocaine Topical Aerosol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lidocaine aerosol 500 mg (100 mg/ml; Xylocain aerosol, ASTRA, Sweden)
Trial: 6398021
Drug: Immunosuppressive drug
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immunosuppressive drug therapy with plasmapheresis (PP)
Trial: 30941124
Drug: T cell
RxNorm normalized name: CD4CAR T cells
DrugBank: Anti-CD4 CAR T-cell therapy (DB17281)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: T cell therapy targeting HLA‐A02 restricted HIV antigen epitopes
Trial: 17568252
Drug: 4 weeks
RxNorm normalized name: risperiDONE 75 mg/4 weeks intramuscular powder for injection, extended release
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 weeks of daily 6x15 min ergometer training at submaximal intensity plus 1 h/week group exercise session followed by 5 months of home-based ergometer training of 30 min/day plus 1 h/week group exercise session
Trial: 12062596
Drug: Induction chemotherapy
RxNorm normalized name: human sputum, Bordetella pertussis infected
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Induction chemotherapy (vinblastine 5 mg/m(2) i.v. bolus weekly for the first 5 weeks, and cisplatin, 100 mg/m(2) i.v. on Days 1 and 29) followed by concurrent chemotherapy/radiotherapy (cisplatin 75 mg/m(2) i.v. on Days 50, 71, and 92) during thoracic radiotherapy (63 Gy in 34 fractions during 7 weeks starting on Day 50)
Trial: 12062596
Drug: Concurrent chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Concurrent chemotherapy and hyperfractionated radiotherapy starting on Day 1 with a total dose of 69.6 Gy in 58 fractions during 6 weeks, 1.2 Gy/fraction b.i.d. (cisplatin, 50 mg/m(2) i.v. on Days 1 and 8, and oral VP‐16, 50 mg b.i.d. for 10 days only on the days of thoracic radiotherapy repeated on Day 29)
Trial: 9593141
Drug: sorivudine (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: sorivudine (40 mg once daily)
Trial: 9593141
Drug: acyclovir (800
FDA approved: no
EMA approved: no
PMDA approved: no
Description: acyclovir (800 mg five times daily)
Trial: 278688
Drug: Toothbrush with
RxNorm normalized name: Suction Toothbrush with Corinz Oral Rinse KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Toothbrush with supervised oral cleaning
Trial: 278688
Drug: Mefaka (chewing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mefaka (chewing stick) with supervised oral cleaning
Trial: 31301476
Drug: Self-guided internet-delivered
RxNorm normalized name: DELIVER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Self-guided internet-delivered cognitive behavior therapy (ICBT)
Trial: 26094635
Drug: Ultrasound-guided percutaneous
RxNorm normalized name: ULTRASOUND
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ultrasound-guided percutaneous microwave ablation with ethanol injection
Trial: 26094635
Drug: Ultrasound-guided percutaneous
RxNorm normalized name: ULTRASOUND
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ultrasound-guided percutaneous microwave ablation without ethanol injection (control group)
Trial: 23489301
Drug: Alogliptin (12.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alogliptin (12.5 and 25 mg daily)
Trial: 23489301
Drug: Comparator therapies
RxNorm normalized name: Theraplex Eczema Therapy
DrugBank: Colloidal oatmeal (DB11286)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Comparator therapies (other antidiabetic agents)
Trial: 19114436
Drug: Occupational therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Occupational therapy for 12 months
Trial: 11416883
Drug: Intravenous BH4
RxNorm normalized name: 6R-BH4
DrugBank: Sapropterin (DB00360)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Intravenous BH4 (10 mg/kg)
Trial: 9595286
Drug: Spironolactone (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Spironolactone (25 mg/day for 16 weeks)
Trial: 7801667
Drug: molsidomine 8
RxNorm normalized name: molsidomine 8 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: molsidomine 8 mg bid
Trial: 3050654
Drug: Clindamycin 300
RxNorm normalized name: clindamycin 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clindamycin 300 mg twice daily for 7 days
Trial: 1754753
Drug: Metronidazole 500
RxNorm normalized name: metronidazole 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metronidazole 500 mg twice daily for 7 days
Trial: 30665513
Drug: Supervised ground-based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Supervised ground-based walking training (30–45 min, 2–3 times weekly for 8–10 weeks)
Trial: 25945012
Drug: PDN+MTD 500
RxNorm normalized name: IL-2 pDNA
DrugBank: IL-2 pDNA (DB05935)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PDN+MTD 500 mg three times daily
Trial: 25945012
Drug: PTX+MTD 500
RxNorm normalized name: PTX-100
DrugBank: PTX-100 (DB18125)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PTX+MTD 500 mg three times daily
Trial: 21285094
Drug: Collaborative model
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Collaborative model of depression care (problem-solving therapy, antidepressants, symptom monitoring, and relapse prevention)
Trial: 19920418
Drug: Double-injection technique
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Double-injection technique
Trial: 19920418
Drug: Single-injection technique
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single-injection technique
Trial: 17899571
Drug: Vaginal progesterone
RxNorm normalized name: progesterone Vaginal Insert
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vaginal progesterone (90 mg daily)
Trial: 3514833
Drug: Vitamin D
RxNorm normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin D supplementation (750 IU daily from 2nd week of life)
Trial: 31515152
Drug: High-flow oxygen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-flow oxygen therapy (HFOT)
Trial: 25762401
Drug: Placebo with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo with free-saline solution
Trial: 18634501
Drug: One intradermal
RxNorm normalized name: Fluzone Intradermal 2011-2012
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One intradermal injection of 0.1 ml (1 site) followed by two booster vaccinations of 0.1 ml (1 site) intradermally on days 0 and 3
Trial: 18634501
Drug: Three intradermal
RxNorm normalized name: three-lobe sage extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Three intradermal injections within one week
Trial: 18634501
Drug: Three injections
RxNorm normalized name: three-lobe sage extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Three injections administered over 3-4 weeks with two booster vaccinations on days 0 and 3 one year later
Trial: 16060244
Drug: Surgical treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Surgical treatment (craniotomy or endovascular coil embolization)
Trial: 16060244
Drug: Natural course
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Natural course observation (no surgical treatment)
Trial: 30008589
Drug: LdT (telbivudine)
RxNorm normalized name: LDT
DrugBank: Telbivudine (DB01265)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: LdT (telbivudine) treatment
Trial: 30008589
Drug: Observation group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Observation group (no antiviral therapy)
Trial: 27779639
Drug: Light exercise
RxNorm normalized name: kaolin light
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Light exercise program (2-hour education session, five weekly 90-minute exercise training sessions, and home-based self-managed exercise program)
Trial: 25532087
Drug: PCEA (bolus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PCEA (bolus - 5 ml, lockout interval - 15 minutes, basal rate - 0 ml) with bupivacaine 0.08% and fentanyl 2 µg/ml
Trial: 25532087
Drug: CEA (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CEA (10 ml/h) with bupivacaine 0.08% and fentanyl 2 µg/ml
Trial: 19584823
Drug: No treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No treatment (controls), n=86
Trial: 17081656
Drug: 6 isoenergetic
RxNorm normalized name: Octisalate 0.05 g in 1 mL / Avobenzone 0.03 g in 1 mL / Octinoxate 0.029 g in 1 mL / Octocrylene 0.022 g in 1 mL TOPICAL LOTION [For Men Maca Root Energetic Face Protector SPF 15]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6 isoenergetic meals fed hourly
Trial: 15604943
Drug: Administration of
RxNorm normalized name: IV solutions used in parenteral administration of fluids, electrolytes and nutrients
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administration of milk
Trial: 15604943
Drug: Administration of
RxNorm normalized name: IV solutions used in parenteral administration of fluids, electrolytes and nutrients
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administration of milk plus water
Trial: 1782715
Drug: Topical antibiotic/steroid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical antibiotic/steroid mixture with alternate day dressings
Trial: 1782715
Drug: Topical antibiotic/steroid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical antibiotic/steroid mixture with sump filling
Trial: 6168426
Drug: MOP (the
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MOP (the same combination without prednisone)
Trial: 6168426
Drug: B‐MOPP (MOPP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: B‐MOPP (MOPP plus bleomycin at low dosage)
Trial: 6168426
Drug: CVB combination
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CVB combination (CCNU, vinblastine and bleomycin)
Trial: 19034466
Drug: Anterolateral (A-L)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anterolateral (A-L) trans-tibia approach
Trial: 18089334
Drug: Valganciclovir oral
RxNorm normalized name: valganciclovir Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Valganciclovir oral solution (900 mg)
Trial: 18089334
Drug: Valganciclovir tablets
RxNorm normalized name: Valganciclovir Tablets
DrugBank: Valganciclovir (DB01610)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Valganciclovir tablets (900 mg)
Trial: 18089334
Drug: Valganciclovir oral
RxNorm normalized name: valganciclovir Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Valganciclovir oral solution
Trial: 18089334
Drug: Valganciclovir tablets
RxNorm normalized name: Valganciclovir Tablets
DrugBank: Valganciclovir (DB01610)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Valganciclovir tablets
Trial: 18089334
Drug: Valganciclovir oral
RxNorm normalized name: valganciclovir Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Valganciclovir oral solution vs tablets
Trial: 18089334
Drug: Valganciclovir oral
RxNorm normalized name: valganciclovir Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Valganciclovir oral solution and tablets
Trial: 8791950
Drug: Lansoprazole 30
RxNorm normalized name: lansoprazole 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lansoprazole 30 mg b.d., clarithromycin 250 mg b.d., metronidazole 400 mg b.d. (cohort A)
Trial: 8791950
Drug: Lansoprazole 30
RxNorm normalized name: lansoprazole 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lansoprazole 30 mg b.d., clarithromycin 250 mg b.d., tetracycline 300 mg b.d. (cohort B)
Trial: 6209488
Drug: Nicardipine 5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nicardipine 5 mg i.v.
Trial: 6209488
Drug: Nicardipine 10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nicardipine 10 mg i.v.
Trial: 6209488
Drug: Nicardipine 2.5
RxNorm normalized name: niCARdipine 2.5 mg/mL intravenous solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nicardipine 2.5 mg i.v. after beta-blockade with propranolol
Trial: 31180258
Drug: FCL plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FCL plus topical SC‐CM
Trial: 31180258
Drug: FCL plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FCL plus topical PRP
Trial: 27302306
Drug: Supportive-expressive discussion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Supportive-expressive discussion groups (12 weekly 90-min sessions)
Trial: 25419597
Drug: Low-dose oral,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-dose oral, delayed-release mesalamine (27-71 mg · g(‐1) · day(‐1))
Trial: 25419597
Drug: High-dose oral,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose oral, delayed-release mesalamine (53-118 mg · g(‐1) · day(‐1))
Trial: 25419597
Drug: Low-dose oral,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-dose oral, delayed-release mesalamine
Trial: 25419597
Drug: High-dose oral,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose oral, delayed-release mesalamine
Trial: 18379511
Drug: Hydroxyzine (atarax)
RxNorm normalized name: hydroxyzine hydrochloride Oral Solution [Atarax]
DrugBank: Hydroxyzine (DB00557)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hydroxyzine (atarax) as a substitutive therapy after immediate withdrawal of BDT
Trial: 18379511
Drug: Placebo therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo therapy during continuous withdrawal of BDT over 14 days
Trial: 10385768
Drug: Intravenous continuous
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous continuous dobutamine
Trial: 26293185
Drug: Mixture of
RxNorm normalized name: OCTADECANOL (MIXTURE OF ISOMERS)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mixture of autogenous and xenogenous bone for conventional sinus floor augmentation
Trial: 7651682
Drug: Alkalinized anesthetic
RxNorm normalized name: Gelato Anesthetic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alkalinized anesthetic solution
Trial: 7651682
Drug: Nadbath injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nadbath injection
Trial: 3046631
Drug: Dilevalol (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dilevalol (200 mg)
Trial: 349379
Drug: Concurrent quality
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Concurrent quality assurance (CQA)
Trial: 31712214
Drug: RV521 350
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RV521 350 mg
Trial: 31712214
Drug: RV521 200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RV521 200 mg
Trial: 28727702
Drug: Subcutaneous injection
RxNorm normalized name: EPINEPHRINE 0.3 mg SUBCUTANEOUS INJECTION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous injection of triamcinolone and lidocaine
Trial: 23698171
Drug: Atraumatic restorative
RxNorm normalized name: DRESSING,RESTORE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atraumatic restorative treatment (ART) by dentists
Trial: 23698171
Drug: Atraumatic restorative
RxNorm normalized name: DRESSING,RESTORE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atraumatic restorative treatment (ART) by auxiliaries
Trial: 19188683
Drug: Mitochondrial-targeted antioxidant
RxNorm normalized name: antioxidant 119
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mitochondrial-targeted antioxidant treatment in rats
Trial: 17211305
Drug: 9 mg
RxNorm normalized name: fiber 469 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 9 mg of isobaric bupivacaine with 20 microgr fentanyl
Trial: 17211305
Drug: 13.5 mg
RxNorm normalized name: niacin 13.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 13.5 mg of standardized isobaric 0.5% bupivacaine
Trial: 12776641
Drug: Inhaled isopropyl
RxNorm normalized name: Isopropyl Alcohol
DrugBank: Isopropyl alcohol (DB02325)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled isopropyl alcohol (70%)
Trial: 10671913
Drug: Health authority/pharmaceutical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Health authority/pharmaceutical company collaborative intervention
Trial: 3007219
Drug: Surgical treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Surgical treatment (open biopsy, resection, excision)
Trial: 3231285
Drug: Overall surgical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Overall surgical treatment
Trial: 3007219
Drug: Post-operative chemotherapy
RxNorm normalized name: post oak pollen extract
DrugBank: Quercus stellata pollen (DB10888)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Post-operative chemotherapy
Trial: 23394509
Drug: High-dose inhaled
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose inhaled corticosteroids (ICSs) at doses of two, four, or eight times their maintenance ICS dose for 12 days
Trial: 23394509
Drug: Doubling the
RxNorm normalized name: THE-630
DrugBank: THE-630 (DB16750)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doubling the maintenance dose of ICS
Trial: 18395165
Drug: Statin-fibrate therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Statin-fibrate therapy (control)
Trial: 12645393
Drug: Selegiline (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Selegiline (10 mg/die for six months)
Trial: 9583927
Drug: Aminosidine 12
RxNorm normalized name: Aminosidine
DrugBank: Paromomycin (DB01421)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Aminosidine 12 mg/kg/day for 21 days
Trial: 9583927
Drug: Aminosidine 16
RxNorm normalized name: Aminosidine
DrugBank: Paromomycin (DB01421)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Aminosidine 16 mg/kg/day for 21 days
Trial: 9583927
Drug: Aminosidine 20
RxNorm normalized name: Aminosidine
DrugBank: Paromomycin (DB01421)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Aminosidine 20 mg/kg/day for 21 days
Trial: 9583927
Drug: Sodium stibogluconate
RxNorm normalized name: sodium stibogluconate
DrugBank: Sodium stibogluconate (DB05630)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sodium stibogluconate 20 mg/kg/day for 30 days
Trial: 9583927
Drug: Aminosidine (16
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aminosidine (16 and 20 mg/kg/day)
Trial: 30256277
Drug: Mindfulness meditation
RxNorm normalized name: benzalkonium chloride Topical Foam [Meditize]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mindfulness meditation (daily practice for 21 days)
Trial: 20559255
Drug: Viferon gel
RxNorm normalized name: Uniferon
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Viferon gel (0.5 ml, 4-5 times daily)